Navigation Links
CryoCath announces 2007 fourth quarter and fiscal year end financial results
Date:12/17/2007

50,312,095 54,474,961

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Statements of Operations and Comprehensive Loss and Deficit (unaudited)

Years ended September 30 2007 2006

$ $

REVENUES

Sales (including rental income of

$839,460; 2006 - $320,862) 39,692,191 38,375,896

Cost of sales (including amortization and

console write-downs of $2,789,709; 2006

- $4,245,556) 16,202,821 17,824,668

-------------------------------------------------------------------------

Gross Profit 23,489,370 20,551,228

Surgical distribution rights - 233,358

Interest income 23,489,370 20,784,586

727,198 531,978

-------------------------------------------------------------------------

24,216,568 21,316,564

-------------------------------------------------------------------------

-------------------------------------------------------------------------

EXPENSES

Research and development 12,591,208 11,829,618

Investment tax credits (717,195) (944,172)

-------------------------------------------------------------------------

Net research and development 11,874,013 10,885,446

Administrative 7,574,336 5,963,916

Sales and marketing 24,694,626 27,430,009

Amortization a
'/>"/>

SOURCE CryoCath Technologies Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... technology and the provider of the optimal paper-based e-data capture ... among the Fastest Growing Technology Companies on the Deloitte Technology ... ... (PRWEB) December 16, 2009 -- Kayentis provides ... of handwritten data. Kayentis targets the Healthcare and Life Sciences ...
(Date:12/16/2009)... government report shows, , , WEDNESDAY, Dec. 16 (HealthDay News) ... reached almost 78 years, a record high, federal health ... can expect to live to 80.4 years on average ... from the U.S. Centers for Disease Control and Prevention. ... live longer than their parents, life expectancy in the ...
(Date:12/16/2009)... Dec. 16 New research published ... compounds in pistachios, and molecules present in ... oil decreases levels of an inflammatory marker ... repeats 2). Inflammation is a complex biological ... or irritants, and it underlies functional changes ...
(Date:12/16/2009)... at the heart of diagnostic procedures in cardiology. The ... which accumulates the expertise of European cardiovascular imagers, is ... that it is written with a patient rather than ... the patient, with the aid of imaging. , ... themes involving theory and practice of cardiac imaging and ...
(Date:12/16/2009)... Satisfaction, New Partners and Global Market Expansion , ... ... provider of Feedback Analytics to Web sites and companies, today announced ... 25,000 new customers. Since its launch on July 2008, Kampyle ... 60 languages, and amassed more than 30,000 customers in 191 countries., ...
Breaking Medicine News(10 mins):Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5
... that inflammation associated with the progression of tumors actually ... cancer. // ,The research identifies a mechanism, which ... late stages of prostate cancer development. The findings by ... of Gene Regulation and Signal Transduction, and colleagues may ...
... and Drug Administration (FDA) today approved Soliris (eculizumab), the ... (PNH), a rare type of blood disorder that can ... as an Orphan Drug and is a new molecular ... United States. ,"This product is important in ...
... prevention efforts are fueling the spread of HIV in Afghanistan, ... the Times, there are 69-recorded cases of HIV in the ... cases is much higher. The World Health Organization estimates that ... ,Nilufar Egamberdi, a World Bank consultant on HIV/AIDS, said the ...
... nursing home in southern Russia killed at least 63 persons on ... accident took place at a coastal village called Kamyshevatskaya. Emergency workers ... 1 a.m. It took them one hour to reach the village. ... 5 a.m., say officials. ,The incident comes less ...
... international study has come out strongly against the use of ... years. ,According to the Working Group on artificial ... Research on Cancer (IARC), persons who use these tanning beds ... up exposing themselves to higher risks of developing melanoma, the ...
... A new study claims that laughter brings out the humanitarian facet ... aid//. This research was conducted by Mark van Vugt and his ... were involved in this study were made to watch a hilarious ... While playing the game they were given money which they could ...
Other Medicine News:Health News:Inflammation May Play Role in Metastasis of Prostate Cancer 2Health News:Inflammation May Play Role in Metastasis of Prostate Cancer 3Health News:FDA Approves First-of-its-Kind Drug to Treat Rare Blood Disorder 2Health News:Stigma, Lack of Education, Prevent the Spread of HIV in Afghanistan 2
(Date:12/16/2009)... Dec. 16 Frost & Sullivan,s ... looks forward to speaking at the 2010 ... place on January 9, 2010 in Las ... emerging market of consumer-based digital health and ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses ...
(Date:12/16/2009)... 16 Naurex Inc., a new clinical ... other CNS disorders based on its novel GFPA ... at a major medical meeting showed that its ... activity with no signs of the CNS-related side ... receptor(1). The studies also showed that GLYX-13,s ...
(Date:12/16/2009)... Savara, Inc., an inhalation drug delivery company, ... in its Series A financing round, exceeding the targeted ... Funds raised in the Series A round will be ... ,, "We now have the runway and resources ... NanoCluster technology," said Rob Neville, CEO of Savara. ...
Breaking Medicine Technology:Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Pitt researchers find promising candidate protein for cancer prevention vaccines 9472 1Pitt researchers find promising candidate protein for cancer prevention vaccines 9472 2Nanotechnology Transforms Pain Relief 53652 1Nanotechnology Transforms Pain Relief 53652 2Nanotechnology Transforms Pain Relief 53652 3Nanotechnology Transforms Pain Relief 53652 4Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 53650 1Aetna 28 Percent Profit Drop Signals Storm Clouds for Healthcare 53650 2
... MOUNTAIN VIEW, Calif., Feb. 23 MAP,Pharmaceuticals, Inc. ... of its initial,Phase 3 clinical trial of Unit ... with asthma. The Company announced that the ... control as assessed by,changes from baseline in nighttime ...
... 23 People who start smoking before age ... according to a study released today that will be presented ... Seattle, April 25 to May 2, 2009. The study involved ... people in a larger study. The people with MS were ...
Other Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Young Smokers Increase Risk for Multiple Sclerosis 2
Produces vacuum pressures required for 96 well kits...
... pump is perfect for electrophoresis gel drying, ... vacuum of greater than 29 inches of ... well with the Model 583 gel dryer. ... 1/4 and 3/8 inch ID vacuum tubing, ...
Produces vacuum pressures required for 96 well kits...
For vacuum-driven processing of spin columns; Reduced sample handling and accelerated processing; Parallel sample processing using QIAGEN spin columns; Easy cleaning of internal components by simpl...
Medicine Products: